CN118804976A - 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 - Google Patents

用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 Download PDF

Info

Publication number
CN118804976A
CN118804976A CN202280082782.0A CN202280082782A CN118804976A CN 118804976 A CN118804976 A CN 118804976A CN 202280082782 A CN202280082782 A CN 202280082782A CN 118804976 A CN118804976 A CN 118804976A
Authority
CN
China
Prior art keywords
itga1
nucleic acid
acid molecule
variant
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280082782.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·R·费雷拉
J·E·霍罗威茨
K·西米诺维奇
G·阿贝卡西斯
A·巴拉斯
M·C·苏西尤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN118804976A publication Critical patent/CN118804976A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202280082782.0A 2021-12-17 2022-12-16 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 Pending CN118804976A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291194P 2021-12-17 2021-12-17
US63/291,194 2021-12-17
PCT/US2022/081750 WO2023114969A2 (en) 2021-12-17 2022-12-16 Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors

Publications (1)

Publication Number Publication Date
CN118804976A true CN118804976A (zh) 2024-10-18

Family

ID=85158395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280082782.0A Pending CN118804976A (zh) 2021-12-17 2022-12-16 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患

Country Status (7)

Country Link
US (1) US20230192864A1 (https=)
EP (1) EP4448766A2 (https=)
JP (1) JP2024545873A (https=)
CN (1) CN118804976A (https=)
CA (1) CA3240997A1 (https=)
MX (1) MX2024007460A (https=)
WO (1) WO2023114969A2 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
JP2017510552A (ja) * 2014-02-07 2017-04-13 イーフェクター セラピューティクス， インコーポレイテッド 線維性疾患を治療するための方法
EP3458157A4 (en) * 2016-05-19 2020-05-27 Momenta Pharmaceuticals, Inc. METHOD FOR TREATING DISEASES RELATING TO FIBROSE AND SYSTEMIC Sclerosis
WO2018159432A1 (ja) * 2017-03-03 2018-09-07 ロート製薬株式会社 間葉系幹細胞及び医薬組成物
CN111643649A (zh) * 2020-05-20 2020-09-11 博奥生物集团有限公司 防治免疫相关疾病的中药材及其组合物

Also Published As

Publication number Publication date
CA3240997A1 (en) 2023-06-22
WO2023114969A2 (en) 2023-06-22
JP2024545873A (ja) 2024-12-13
US20230192864A1 (en) 2023-06-22
EP4448766A2 (en) 2024-10-23
MX2024007460A (es) 2024-07-09
WO2023114969A3 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
JP7574206B2 (ja) ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療
CA3191030A1 (en) Treatment of sepsis with pcsk9 and ldlr modulators
CA3167756A1 (en) Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors
JP2024522148A (ja) インターフェロン誘導ヘリカーゼｃドメイン１（ｉｆｉｈ１）阻害剤による乾癬の治療
JP2024521224A (ja) 神経原性座位Ｎｏｔｃｈホモログタンパク質３（ＮＯＴＣＨ３）剤による脳血管疾患の治療
CN118541481A (zh) 用分化簇109(cd109)抑制剂治疗骨矿物质密度降低的方法
JP2024541089A (ja) ナトリウム電位依存性チャネルαサブユニット１１（ＳＣＮ１１Ａ）阻害剤による頭痛及び片頭痛の治療方法
CN118804976A (zh) 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患
US20250136996A1 (en) Treatment of smoking with cholinergic receptor nicotinic beta 3 subunit (chrnb3) inhibitors
US20230383351A1 (en) Rare Variants In Hematopoietic Stem Cells (HSC) And Hematopoietic Progenitor Cells (HPC) Associated With Somatic Alterations Of The Blood
CN118613584A (zh) 使用内质网氨基肽酶1(erap1)抑制剂治疗葡萄膜炎
CN118891050A (zh) 用Rho鸟嘌呤核苷酸交换因子12(ARHGEF12)抑制剂治疗青光眼
CN117795075A (zh) 使用溶质载剂家族27成员3(slc27a3)抑制剂治疗哮喘的方法
JP2024536491A (ja) 小胞体アミノペプチダーゼ１（ｅｒａｐ１）阻害剤によるぶどう膜炎の治療
JP2024524526A (ja) α－Ｎ－アセチルガラクトサミニドα－２，６－シアリルトランスフェラーゼ５（ＳＴ６ＧＡＬＮＡＣ５）阻害剤による認知障害の治療
WO2023141577A2 (en) Methods of improving health with apolipoprotein e (apoe) inhibitors
JP2024524374A (ja) 溶質輸送体ファミリー９アイソフォームａ３調節因子２（ｓｌｃ９ａ３ｒ２）阻害剤による高血圧症の治療
CN118541479A (zh) 用卵黄样羧肽酶(cpvl)抑制剂治疗皮肤癌的方法
CN118265529A (zh) 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗
CN117940565A (zh) 用Wnt家族成员5B(WNT5B)抑制剂治疗骨矿物质密度降低

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination